5-hydroxytryptamine receptor 7 activity modulators and their method of use

Patent metadata

Field	Value
Publication number	US-10287274-B2
Application number	US-201715716773-A
Country	US
Kind code	B2
Filing date	Sep 27, 2017
Priority date	Mar 11, 2013
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

First claim

What is claimed is:

1. A compound having formula (III):

or an enantiomer, diastereoisomer, or pharmaceutically acceptable salt thereof, wherein:
R 2a is selected from a group consisting of hydrogen, C 1-6 linear alkyl, C 1-6 branched alkyl, and phenyl;
R 2b is selected from a group consisting of C 1-6 linear alkyl, C 1-6 branched alkyl, and phenyl;
or
R 2a and R 2b are taken together with the atom to which they are bound to form a ring having from 3 to 7 ring atoms;
R 3 is selected from a group consisting of C 1-6 linear alkyl, C 1-6 branched alkyl, C 3-7 cycloalkyl,

naphthylen-1-yl, naphthylen-2-yl, optionally substituted phenyl, 4-1H-indol-5-yl, 4-benzo[c][1,2,5]thiadiazole, optionally substituted pyridin-2-yl, optionally substituted pyridin-3-yl, and optionally substituted pyridin-4-yl,
wherein the optionally substituted phenyl is substituted with 0 to 2 units selected from halogen, —CN, —NO 2 , —OH, —NH 2 , C 1-6 alkyl, C 3-7 branched alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 2-8 alkenyl, and C 2-8 alkynyl; and wherein the optionally substituted phenyl is substituted with 0 to 1 units selected from C 3-7 cycloalkyl, aryl, heterocycle, and heteroaryl; and wherein the optionally substituted pyridin-2-yl, the optionally substituted pyridin-3-yl, and the optionally substituted pyridin-4-yl are each independently substituted with 0 to 2 units selected from halogen, —CN, —NO 2 , —OH, —NH 2 , C 1-6 alkyl, C 3-7 branched alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 2-8 alkenyl, and C 2-8 alkynyl; and wherein the optionally substituted pyridin-2-yl, the optionally substituted pyridin-3-yl, and the optionally substituted pyridin-4-yl are each independently substituted with 0 to 1 units selected from C 3-7 cycloalkyl, aryl, heterocycle, and heteroaryl;
R 4 is optionally substituted phenyl,
wherein the optionally substituted phenyl is substituted with 0 to 2 units selected from halogen, —CN, —NO 2 , —OH, —NH 2 , C 1-6 alkyl, C 3-7 branched alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 2-8 alkenyl, and C 2-8 alkynyl;
and wherein the optionally substituted phenyl is substituted with 0 to 1 units selected from C 3-7 cycloalkyl, aryl, heterocycle, and heteroaryl;

n is 2 or 3;
and m is 1 or 2.

2. The compound of claim 1 or an enantiomer, diastereoisomer, or pharmaceutically acceptable salt thereof, wherein
R 3 is selected from a group consisting of naphthylen-1-yl, naphthylen-2-yl, phenyl, 4-1H-indol-5-yl, 4-benzo[c][1,2,5]thiadiazole, 4-methylphenyl, 4-cyanophenyl, 2-methoxyphenyl, 4-nitrophenyl, 2-hydroxyphenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-aminophenyl, 2,4-dimethylphenyl, 2-isopropylPhenyl, 2-methylphenyl, 2,6-dimethylphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 2-cyanophenyl, 2-cyano-4-nitrophenyl, 2-acetamidophenyl, 2-Iodophenyl, 2-pyrrol-1-yl-phenyl, 2-phenylphenyl, 2-morpholinophenyl, 2,6-diisopropylphenyl, 2-tert-butylphenyl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.

3. The compound of claim 1 , having the formula (XXXXV):

or an enantiomer, diastereoisomer, or pharmaceutically acceptable salt thereof, wherein
R 4 is selected from the group consisting of phenyl, 4-methylphenyl, 4-cyanophenyl, 2-methoxyphenyl, 4-nitrophenyl, 2-hydroxyphenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-aminophenyl, 2,4-dimethylphenyl, 2-isopropylPhenyl, 2-methylphenyl, 2,6-dimethylphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 2-cyanophenyl, 2-cyano-4-nitrophenyl, 2-acetamidophenyl, 2-Iodophenyl, 2-pyrrol-1-yl-phenyl, 2-phenylphenyl, 2-morpholinophenyl, 2,6-diisopropylphenyl, and 2-tert-butylphenyl.

4. A composition comprising at least one compound according to claim 1 .

5. The composition according to claim 4 , further comprising at least one excipient.

6. A compound selected from the group consisting of:
(R)-1-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-3-one;
(S)-1-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-3-one;
(R)-5-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-4,4-dimethyldihydrofuran-2(3H)-one;
(S)-5-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-4,4-dimethyldihydrofuran-2(3H)-one;
(R)-1-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-3-one;
(S)-1-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-3-one;
(R)-4,4-dimethyl-5-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one;
(S)-4,4-dimethyl-5-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one;
or a pharmaceutically acceptable salt thereof.

7. A composition comprising at least one compound according to claim 6 .

8. The composition according to claim 7 , further comprising at least one excipient.

9. A method of treating a disease wherein the activity of the 5-hydroxytryptamine receptor 7 (5-HT 7 ) is dysregulated, wherein the disease is circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder, said method comprising administering to a subject an effective amount of at least one compound according to the claim 1 to treat the disease.

10. The method of claim 9 , wherein the at least one compound is administered in a composition further comprising at least one excipient.

11. A compound having the formula (XXXXIX):

or an enantiomer, diastereoisomer, or pharmaceutically acceptable salt thereof, wherein
R 2a is selected from a group consisting of hydrogen, C 1-6 linear alkyl, and C 1-6 branched alkyl;
R 2b is selected from a group consisting of C 1-6 linear alkyl and C 1-6 branched alkyl;
or
R 2a and R 2b are taken together with the atom to which they are bound to form a ring having from 3 to 7 ring atoms;
R 6a , R 6b , R 6c , and R 6d are each independently selected from a group consisting of hydrogen, halogen, OH, C 1-6 linear alkyl, C 1-6 branched alkyl, C 1-6 alkoxy, C 1-6 fluoroalkyl, C 1-6 fluoroalkoxy, cyano, NH(C 1-3 alkyl), N(C 1-3 alkyl) 2 , NHC(O)R 7 , C(O)NHR 7 , C(O)N(R 7 ) 2 , SH, SC 1-6 alkyl, SO 2 NH 2 , SO 2 NHR 7 , SO 2 R 7 , and NHSO 2 R 7 ;
At least two of R 6a , R 6b , R 6c , and R 6d are hydrogen;
R 7 is independently selected at each occurrence from a group consisting of C 1-3 linear alkyl, C 3-5 branched alkyl, and C 3-6 cycloalkyl; and
n is 2 or 3.

12. A composition comprising at least one compound according to claim 11 .

13. A composition according to claim 12 , further comprising at least one excipient.

Assignees

• Univ Temple

Inventors

• Canney Daniel J
• Blass Benjamin E
• Gao Rong
• Abou-Gharbia Magid

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title